We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts forecast that Boston Scientific (BSX - Free Report) will report quarterly earnings of $0.80 per share in its upcoming release, pointing to a year-over-year increase of 6.7%. It is anticipated that revenues will amount to $5.19 billion, exhibiting an increase of 11.2% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Boston Scientific metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Net Sales- Cardiovascular- Worldwide' at $3.48 billion. The estimate indicates a change of +12.9% from the prior-year quarter.
Analysts forecast 'Net Sales- MedSurg- Worldwide' to reach $1.63 billion. The estimate points to a change of +3.6% from the year-ago quarter.
It is projected by analysts that the 'Net Sales- MedSurg- Neuromodulation- Worldwide' will reach $296.10 million. The estimate suggests a change of +9.3% year over year.
The consensus estimate for 'Net Sales- MedSurg- Urology- Worldwide' stands at $675.26 million. The estimate indicates a change of +6.7% from the prior-year quarter.
Analysts expect 'Net Sales- MedSurg- Endoscopy- Worldwide' to come in at $715.17 million. The estimate indicates a change of +6.3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Cardiovascular- Electrophysiology- Worldwide' will likely reach $887.07 million. The estimate indicates a change of +21.5% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- Cardiovascular- Watchman- Worldwide' reaching $524.11 million. The estimate indicates a year-over-year change of +23.3%.
According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide' should come in at $598.00 million. The estimate suggests a change of +3.5% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- Cardiovascular- Interventional Cardiology Therapies- Worldwide' of $1.21 billion. The estimate indicates a change of +74.3% from the prior-year quarter.
Analysts predict that the 'Geographic Revenue- U.S.' will reach $3.28 billion. The estimate suggests a change of +11% year over year.
Based on the collective assessment of analysts, 'Geographic Revenue- Rest of the World' should arrive at $1.89 billion. The estimate indicates a year-over-year change of +10.9%.
Over the past month, Boston Scientific shares have recorded returns of -9.3% versus the Zacks S&P 500 composite's +5.2% change. Based on its Zacks Rank #3 (Hold), BSX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts forecast that Boston Scientific (BSX - Free Report) will report quarterly earnings of $0.80 per share in its upcoming release, pointing to a year-over-year increase of 6.7%. It is anticipated that revenues will amount to $5.19 billion, exhibiting an increase of 11.2% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Boston Scientific metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Net Sales- Cardiovascular- Worldwide' at $3.48 billion. The estimate indicates a change of +12.9% from the prior-year quarter.
Analysts forecast 'Net Sales- MedSurg- Worldwide' to reach $1.63 billion. The estimate points to a change of +3.6% from the year-ago quarter.
It is projected by analysts that the 'Net Sales- MedSurg- Neuromodulation- Worldwide' will reach $296.10 million. The estimate suggests a change of +9.3% year over year.
The consensus estimate for 'Net Sales- MedSurg- Urology- Worldwide' stands at $675.26 million. The estimate indicates a change of +6.7% from the prior-year quarter.
Analysts expect 'Net Sales- MedSurg- Endoscopy- Worldwide' to come in at $715.17 million. The estimate indicates a change of +6.3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Cardiovascular- Electrophysiology- Worldwide' will likely reach $887.07 million. The estimate indicates a change of +21.5% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- Cardiovascular- Watchman- Worldwide' reaching $524.11 million. The estimate indicates a year-over-year change of +23.3%.
According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide' should come in at $598.00 million. The estimate suggests a change of +3.5% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- Cardiovascular- Interventional Cardiology Therapies- Worldwide' of $1.21 billion. The estimate indicates a change of +74.3% from the prior-year quarter.
Analysts predict that the 'Geographic Revenue- U.S.' will reach $3.28 billion. The estimate suggests a change of +11% year over year.
Based on the collective assessment of analysts, 'Geographic Revenue- Rest of the World' should arrive at $1.89 billion. The estimate indicates a year-over-year change of +10.9%.
View all Key Company Metrics for Boston Scientific here>>>Over the past month, Boston Scientific shares have recorded returns of -9.3% versus the Zacks S&P 500 composite's +5.2% change. Based on its Zacks Rank #3 (Hold), BSX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .